The Latest in St. Jude Research on Blood Cancers and Blood Disorders
qimono / Pixabay

The Latest in St. Jude Research on Blood Cancers and Blood Disorders

According to a story from EurekAlert!, the 60th Annual Meeting of the American Society of Hematology featured a number of different presentations of the latest research from St. Jude Children's…

Continue Reading The Latest in St. Jude Research on Blood Cancers and Blood Disorders
Homocystinuria is More Common Than We Thought, It’s Just Not Detected Well in NBS
https://pixabay.com/en/baby-care-child-cute-hand-face-20339/

Homocystinuria is More Common Than We Thought, It’s Just Not Detected Well in NBS

Most patients diagnosed with Homocystinuria (HCU), a rare metabolic disorder, don't receive their diagnosis until later in life. Scientists were at a loss for why patients with phenylketonuria (PKU), a similar…

Continue Reading Homocystinuria is More Common Than We Thought, It’s Just Not Detected Well in NBS
Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy
stevepb / Pixabay

Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy

According to a story from globenewswire.com, the biopharmaceutical company Marinus Pharmaceuticals, Inc., recently announced the presentation of Phase 2 clinical trial of the drug ganaxolone as a treatment for CDKL5…

Continue Reading Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy
PKU and Living Medicines: Spotlight Synlogic  
https://pixabay.com/en/seattle-washington-city-state-3465797/

PKU and Living Medicines: Spotlight Synlogic  

Press releases earlier this year on biotech company, Synlogic, announced quite favorable results on both pre-clinical and clinical data on a unique application of synthetic biology for the rare disease, phenylketonuria (PKU). In just…

Continue Reading PKU and Living Medicines: Spotlight Synlogic  
Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia
crystal710 / Pixabay

Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia

According to a story from PR Newswire, the 60th Annual Meeting of the American Society of Hematology has been generating a lot of press lately as many groundbreaking studies, research,…

Continue Reading Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia
Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy
frolicsomepl / Pixabay

Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy

According to a story from Market Screener, an analysis of real-world data (data gathered outside of the clinical setting) suggests that the drug eltrombopag, marketed as Revolade, offers substantial advantages…

Continue Reading Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy
Early Dose-Escalation Data for Potential Treatment for Chronic Lymphocytic Leukemia Released
jarmoluk / Pixabay

Early Dose-Escalation Data for Potential Treatment for Chronic Lymphocytic Leukemia Released

According to a story from BioPortfolio, the global biopharmaceutical company Celgene Corporation recently announced the release of early data from the dose-escalation portion of a Phase 1/2 clinical trial of lisocabtagene…

Continue Reading Early Dose-Escalation Data for Potential Treatment for Chronic Lymphocytic Leukemia Released
International Experts Met with Goal to Improve Care for Chronic Myelomonocytic Leukemia Patients
https://pixabay.com/en/earth-planet-space-satellite-1913747/

International Experts Met with Goal to Improve Care for Chronic Myelomonocytic Leukemia Patients

Chronic myelomonocytic leukemia, or CMML, is a rare condition. However, it has similarities to myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). That being said, it still a unique diagnosis, and…

Continue Reading International Experts Met with Goal to Improve Care for Chronic Myelomonocytic Leukemia Patients

Presentations Demonstrate Promising Advances in Blood Cancers and Blood Disorders

According to a story from PR Newswire, presentations at the 60th annual American Society of Hematology Meeting and Exposition are highlighting the results of four large scale clinical trials that…

Continue Reading Presentations Demonstrate Promising Advances in Blood Cancers and Blood Disorders
Potential New Treatment for Huntington’s Disease Granted Orphan Drug Designation
Source: Pixabay.com

Potential New Treatment for Huntington’s Disease Granted Orphan Drug Designation

Huntington's Disease is a neurodegenerative condition caused by a genetic mutation. It results in progressive decline of motor skills. It also affects cognitive function. Patients experience decline for 15-20 years…

Continue Reading Potential New Treatment for Huntington’s Disease Granted Orphan Drug Designation

Potential New Treatment for Amyotrophic Lateral Sclerosis which Doesn’t Require Swallowing!

Amyotrophic lateral sclerosis (ALS) is a condition which affects the bodies nerve cells. It's neurodegenerative and progressive, causing the patient muscle weakness and muscle atrophy. It eventually results in paralysis.…

Continue Reading Potential New Treatment for Amyotrophic Lateral Sclerosis which Doesn’t Require Swallowing!
A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients
Source: Pixabay.com

A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients

Mantle cell lymphoma is caused by a genetic mutation which  produces cancerous white blood cells. Of course, these are the cells which fight infection in a normal body. Therefore in…

Continue Reading A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients